Advanced Hepatocellular Carcinoma Clinical Trials

172 clinical trials for Advanced Hepatocellular Carcinoma across international registries, including 50 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial — RECRUITING · PHASE1
• Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. — RECRUITING · PHASE1
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
• HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma — RECRUITING · PHASE2
• Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer — RECRUITING · PHASE1
• Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial — RECRUITING · PHASE3
• A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma — RECRUITING · PHASE1
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
• A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma — RECRUITING · PHASE2
• AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease — RECRUITING · PHASE1
• An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma — RECRUITING · PHASE3
• Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment — RECRUITING
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer — RECRUITING · PHASE2
• Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC — RECRUITING · PHASE1
• Phase 2 Study of WGI-0301 for Advanced HCC — RECRUITING · PHASE2
• Ligufalimab and Cadonilimab in Advanced Liver Cancers — RECRUITING · PHASE2
• Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer — RECRUITING · PHASE2
• A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) — RECRUITING · NA
• A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion — RECRUITING · PHASE2
• Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma — RECRUITING · PHASE3
• Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma — RECRUITING · PHASE2
• A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment — RECRUITING · PHASE1
• Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma — RECRUITING
• A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients — RECRUITING · PHASE1
• A RANDOMIZED PHASE 2 STUDY OF CASDOZOKITUG IN COMBINATION WITH TORIPALIMAB PLUS BEVACIZUMAB IN PARTICIPANTS WITH UNRESECTABLE AND/OR LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA — RECRUITING · PHASE2
• A PHASE III, RANDOMISED, OPEN-LABEL, SPONSOR-BLINDED, MULTICENTRE STUDY OF RILVEGOSTOMIG IN COMBINATION WITH BEVACIZUMAB WITH OR WITHOUT TREMELIMUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (ARTEMIDE-HCC01) — RECRUITING · PHASE3
• Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma — RECRUITING · PHASE2
• A MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF TYRA-430 IN ADVANCED HEPATOCELLULAR CARCINOMA AND OTHER SOLID TUMORS WITH ACTIVATING FGF/FGFR PATHWAY ABERRATIONS (SURF431) — RECRUITING
• Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma — RECRUITING
• dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma — RECRUITING · NA
• Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study — RECRUITING · PHASE2
• Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma — RECRUITING · NA
• Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma — RECRUITING · NA
• Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma — RECRUITING · NA
• Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) — RECRUITING · PHASE3
• A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma — RECRUITING · PHASE2
• A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma — RECRUITING · NA
• A PHASE 1/2, SAFETY CONFIRMATION AND DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF RELATLIMAB IN COMBINATION WITH NIVOLUMAB AND BEVACIZUMAB IN TREATMENT-NAIVE ADVANCED/METASTATIC HEPATOCELLULAR CARCINOMA (RELATIVITY-106) — RECRUITING · PHASE1
• A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF CABOZANTINIB (XL184) IN COMBINATION WITH ATEZOLIZUMAB VERSUS SORAFENIB IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO HAVE NOT RECEIVED PREVIOUS SYSTEMIC ANTICANCER THERAPY — RECRUITING · PHASE3
• PEMBROLIZUMAB AND STEREOTACTIC RADIOTHERAPY COMBINED IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA - A PHASE II STUDY (PEMRAD) — RECRUITING · PHASE2
• A PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) VS. BEST SUPPORTIVE CARE AS SECOND-LINE THERAPY IN SUBJECTS WITH PREVIOUSLY SYSTEMICALLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (KEYNOTE-240) — RECRUITING · PHASE3

Refine this search